Biorem (FRA:R6D) Cyclically Adjusted Revenue per Share: €0.79 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:R6D Biorem Inc FRA:R6D
88 GF Score
Price €2.06
GF Value €1.97
! 2 Warning Signs
View Full Analysis

What is Biorem Cyclically Adjusted Revenue per Share?

Biorem FRA:R6D 88 Cyclically Adjusted Revenue per Share is €0.79 as of Jun. 2026. GuruFocus rates FRA:R6D with a GF Score™ of 88/100 and a GF Value™ of €1.97. The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Biorem's adjusted revenue per share for the three months ended in Jun. 2026 was €0.516. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €0.79 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Biorem's average Cyclically Adjusted Revenue Growth Rate was 19.60% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 9.80% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 8.30% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was -0.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Biorem was 9.80% per year. The lowest was -9.50% per year. And the median was -1.70% per year.

As of today (2026-08-02), Biorem's current stock price is €2.06. Biorem's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was €0.79. Biorem's Cyclically Adjusted PS Ratio of today is 2.61.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Biorem was 2.99. The lowest was 0.19. And the median was 0.76.


Biorem  (FRA:R6D) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Biorem's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=2.06/0.79
=2.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Biorem was 2.99. The lowest was 0.19. And the median was 0.76.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Biorem Cyclically Adjusted Revenue per Share Related Terms


Biorem Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Biorem's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biorem Cyclically Adjusted Revenue per Share Chart

Biorem Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.74

Biorem Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.64 0.67 0.74 0.76 0.79

FRA:R6D vs VLTO, ZWS, CECO: Cyclically Adjusted Revenue per Share Comparison

For the Pollution & Treatment Controls subindustry, Biorem's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biorem Cyclically Adjusted PS Ratio vs Industrial Products Industry

For the Industrial Products industry and Industrials sector, Biorem's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Biorem's Cyclically Adjusted PS Ratio falls into.


FRA:R6D
88GF Score
Biorem Inc FRA:R6D
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biorem Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Biorem's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.516/133.5265*133.5265
=0.516

Current CPI (Jun. 2026) = 133.5265.

Biorem Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.070 101.765 0.092
201612 0.136 101.449 0.179
201703 0.137 102.634 0.178
201706 0.098 103.029 0.127
201709 0.092 103.345 0.119
201712 0.147 103.345 0.190
201803 0.063 105.004 0.080
201806 0.087 105.557 0.110
201809 0.074 105.636 0.094
201812 0.184 105.399 0.233
201903 0.070 106.979 0.087
201906 0.107 107.690 0.133
201909 0.114 107.611 0.141
201912 0.071 107.769 0.088
202003 0.097 107.927 0.120
202006 0.101 108.401 0.124
202009 0.059 108.164 0.073
202012 0.122 108.559 0.150
202103 0.054 110.298 0.065
202106 0.095 111.720 0.114
202109 0.076 112.905 0.090
202112 0.262 113.774 0.307
202203 0.218 117.646 0.247
202206 0.269 120.806 0.297
202209 0.328 120.648 0.363
202212 0.388 120.964 0.428
202303 0.140 122.702 0.152
202306 0.189 124.203 0.203
202309 0.243 125.230 0.259
202312 0.391 125.072 0.417
202403 0.222 126.258 0.235
202406 0.267 127.522 0.280
202409 0.531 127.285 0.557
202412 0.330 127.364 0.346
202503 0.164 129.181 0.170
202506 0.322 129.892 0.331
202509 0.372 130.287 0.381
202512 0.565 130.366 0.579
202603 0.235 132.262 0.237
202606 0.516 133.527 0.516

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €0.79 mean?
Biorem (FRA:R6D) has a Cyclically Adjusted Revenue per Share of €0.79 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Biorem and its competitors.
Is Biorem's Cyclically Adjusted Revenue per Share too high?
Biorem's current Cyclically Adjusted Revenue per Share is €0.79. Overall, Biorem has a GF Score™ of 88/100, reflecting its overall financial health beyond just this single metric.
How does Biorem's Cyclically Adjusted Revenue per Share compare to VLTO and ZWS?
Biorem's Cyclically Adjusted Revenue per Share of €0.79 can be compared against companies in the Industrial Products industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for an Industrial Products company?
A good Cyclically Adjusted Revenue per Share depends on the Industrial Products industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Biorem and its competitors. Biorem's current Cyclically Adjusted Revenue per Share is €0.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biorem stock overvalued right now?
Biorem (FRA:R6D) has a current Cyclically Adjusted Revenue per Share of €0.79. The stock's GF Value™ is €1.97, compared to a current price of €2.06 — trading 4.6% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €0.79. Biorem's overall GF Score™ is 88/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Biorem (FRA:R6D), the current Cyclically Adjusted Revenue per Share is €0.79 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biorem (FRA:R6D) Overvalued in 2026?

Based on GuruFocus' analysis, Biorem stock appears to be overvalued. The current stock price of €2.06 is trading 4.6% above its estimated GF Value™ of €1.97.

Key valuation signals for FRA:R6D:

  • Cyclically Adjusted Revenue per Share: €0.79
  • GF Value™: €1.97 vs. price of €2.06 (4.6% above fair value)
  • GF Score™: 88/100 with 2 warning signs

No single metric tells the full story. See the FRA:R6D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Biorem Business Description

Other Exchanges BIRMF:USABRM:Canada
Address 7496 Wellington Road 34, RR Number 3, Puslinch, Guelph, ON, CAN, N1H 6H9
Biorem Inc is an environmental biotechnology company. It is involved in the manufacturing of a comprehensive line of high efficiency air pollution control systems that are used to eliminate odorous and harmful contaminants. The company's products include Biofilters, Biogas Solutions, Multi-Stage Systems, Biotrickling filters, and services such as Media Sampling and Analysis, Biological processes and testing, Media replacements and Spare parts, and other related services. The company derives revenues from the sale of standard products, construction projects for specialized products, and services for repairs and maintenance. The group has a business presence in Canada, the United States, China and others, of which key revenue is derived from the United States.
88GF Score

Get the complete analysis for FRA:R6D

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.06
Price
€1.97
GF Value